Novocure Ltd (NVCR)

[Tkrtape]

They still showed good improvement on the prescription base though. This company is funding many different trials right now....and earnings releases will dog this company for a while because of that. Until I see indications that
this novel approach to cancer is shy on meeting its endpoints, I'm in.
Analyst's lofty expectations drove this stock price down...not the actual performance of the product. Novel approaches to curing cancer are always met with skepticism, which automatically dictates a slow and steady build.
Analysts never pay attention to this reality.
Having a commercial product that is viable is huge. This keeps this company alive and in play for the foreseeable future.